Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: A Randomized Clinical Trial [EDIT-CMD] This first performed randomized, placebo-controlled trial in patients with ANOCA showed that 6 weeks of therapy with diltiazem, when compared with placebo, did not substantially improve CVDys, symptoms, or quality of life, but diltiazem therapy did reduce prevalence of epicardial spasm. 

Download – Sri Lankan Journal of Cardiology Volume 3: Issue 2 – June 2020  

Download – Sri Lankan Journal of Cardiology Volume 3: Issue 1 – January 2020  

Download – Sri Lankan Journal of Cardiology Volume 1: Issue 3 – June 2019  

Sri Lankan Journal of Cardiology Volume 1: Issue 2 – January 2019 Abstract The importance of the microbiome in the pathogenesis of metabolic diseases such as diabetes, hypertension, dyslipidaemia, obesity and cardiovascular diseases are emerging. The gut microbiome, once thought to have a limited function of producing vitamins and in bile acid metabolism is now…

Sri Lankan Journal of Cardiology – Volume 1 Issue 1, June 2018 Abstract Resistant hypertension could be defined as blood pressure that remains elevated despite being treated with 3 anti-hypertensives of which one is a diuretic at maximum tolerable dose. It is an important global health issue associated with morbi dity and mortality. It is…